Investment Thesis
Abeona is a pre-commercial biotech burning cash at $19.8M annually with minimal revenue ($8.7M) and large operating losses despite showing revenue growth. While the strong balance sheet ($61.4M cash, 0.12x leverage) provides 3-4 years of runway, the fundamental lack of profitability, negative cash flow, and uncertain pipeline success warrant a cautious stance without clinical/regulatory catalysts.
Strengths
- Strong liquidity position with $61.4M cash and 5.89x current ratio enabling extended R&D funding
- Conservative balance sheet with 0.12x debt-to-equity ratio minimizing financial distress risk
- Revenue growth of 66.3% YoY shows initial commercialization progress despite small base
Risks
- Severe cash burn of $19.8M annually in operating cash flow with only 3-4 year runway at current rate
- Deep unprofitability with -264.1% operating margin and -195.8% net margin indicating no viable business model yet
- Typical biotech execution risk: clinical trial failures, regulatory setbacks, or pipeline disappointments could require dilutive financing
Key Metrics to Watch
- Operating cash flow trend and burn rate reduction
- Revenue growth sustainability and path to gross profit
- Cash position and runway to profitability or next financing event
Financial Metrics
Revenue
8.7M
Net Income
-17.1M
EPS (Diluted)
$-0.30
Free Cash Flow
-20.7M
Total Assets
198.5M
Cash
61.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-264.1%
Net Margin
-195.8%
ROE
-11.8%
ROA
-8.6%
FCF Margin
-237.8%
Balance Sheet & Liquidity
Current Ratio
5.89x
Quick Ratio
5.70x
Debt/Equity
0.12x
Debt/Assets
27.0%
Interest Coverage
-27.75x
Long-term Debt
18.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:27:40.191633 |
Data as of: 2026-03-31 |
Powered by Claude AI